Rouse M, Twiss J, McKenna SP. Co-calibrating quality-of-life scores from three pulmonary disorders: implications for comparative-effectiveness research. J Med Econ. 2016 Jun;19(6):596-603. doi: 10.3111/13696998.2016.1148700
Kubesch N, de Nazelle A, Guerra S, Westerdahl D, Martinez D, Bouso L, Carrasco-Turigas G, Hoffmann B, Nieuwenhuijsen MJ. Arterial blood pressure responses to short-term exposure to low and high traffic-related air pollution with and without moderate physical activity. Environ Int. 2015 May;22(5):548-57. doi: 10.1177/2047487314555602
Hartley L, Girling A, Bowater R, Lilford R. A multistudy analysis investigating systematic differences in cardiovascular trial results between Europe and Asia. J Epidemiol Community Health. 2015 Apr;69(4):397-404. doi: 10.1136/jech-2013-203646
Brennan VK, Colosia AD, Copley-Merriman K, Mauskopf J, Haas B, Psalencia R. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ. 2014 Jul;17(7):469-80. doi: 10.3111/13696998.2014.915847
Stalhammar J, Stern L, Linder R, Sherman S, Parikh RC, Ariely R, Deschaseaux C, Wikstrom G. The burden of preserved ejection fraction heart failure in a real-world Swedish patient population. J Med Econ. 2014 Jan 25;17(1):43-51. doi: 10.3111/13696998.2013.848808
Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L. Green and black tea for the primary prevention of cardiovascular disease (CVD): a cochrane systematic review. Poster presented at the Society for Social Medicine conference at the Brighton and Sussex Medical School; September 2013. Brighton, United Kingdom. [abstract] J Epidemiol Community Health. 2013 Sep; 67(Suppl 1):A52-3. doi: 10.1136/jech-2013-203126.109
Stalhammar J, Stern L, Linder R, Sherman S, Parikh RC, Ariely R, Wikstrom G. Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. J Med Econ. 2012 May;15(5):938-46.
Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012 Jan 1;15(1):166-74.
Mauskopf JA, Boye KS, Schmitt C, McCollam P, Birt J, Juniper MD, Bakhai A. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. J Med Econ. 2009 Jan 1;12(2):141-53.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.